Macrogenics Inc. is taking a further step into Asia as it joins with I-Mab Biopharma (Shanghai) Co. Ltd. in a collaboration and license agreement to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody. Read More
HONG KONG – Prestige Biopharma Pte. Ltd., a Singapore-headquartered pharmaceutical company under the Prestige Group, has agreed to grant exclusive license to U.K.-based multinational company Mundipharma International Ltd. for distribution and sale of its trastuzumab biosimilar, Tuznue, in western European markets, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria. Read More
PERTH, Australia – The majority of comments were positive for the Therapeutics Goods Administration's proposal for regulating in vitro companion diagnostics (IVD CDx) to ensure the devices receive appropriate premarket scrutiny. Read More
TEL AVIV, Israel – With shares now listed in the U.S. and data from a pivotal trial for its key bladder cancer therapy coming soon, Anchiano Therapeutics Ltd. is poised to ride the wave of interest in gene therapy. Read More
PERTH, Australia – Australian immuno-oncology company Imugene Ltd. signed a deal to in-license an oncolytic virus known as CF33 from the City of Hope Comprehensive Cancer Center in Los Angeles, in a move to bolster its pipeline and open up a new area of growth for the company, said CEO Leslie Chong. Read More
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) received mixed comments from stakeholders on whether it was necessary to implement a formal good clinical practices inspections program in Australia. Many comments questioned how inspectional findings from a proposed pilot program would be released, but most agreed that a formal inspections program would raise compliance and enhance international competitiveness. Read More
Hummingbird Bioscience Pte. Ltd., of Singapore, said it completed an extended series A financing round led by Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore. Hummingbird's existing investors, including Decheng Capital, which led the series A financing round, also participated. Read More
Recce Pharmaceuticals Ltd., of Sydney, appointed John Prendergast independent chair of its board, Graham Melrose executive director and chief research officer and Justin Ward executive director of its board. Read More
